Predict both clinical risk and tumor aggressiveness
Oncotype DX GPS is proven to be an independent predictor of:both clinical risk and tumor aggressiveness after radical prostatectomy for patients with biopsy Gleason scores of 3+3 and 3+41-3.
Interactive report guide
Quickly and easily understand how to interpret the Genomic Prostate Score report.
See sample reports
For patients with:
Getting your results
More than 90% of Oncotype DX GPS results are available within two weeks of the date the specimen is received at the Genomic Health Laboratory. You can access the results through the online physician portal or receive the report by fax.
Compare Report Results